MRK vs ZTS
MRK: Merck & Co. is a leading global biopharmaceutical firm dedicated to delivering life-saving vaccines and innovative therapeutic medicines for major disease areas. ZTS: Zoetis is a leader in the global animal health industry, providing a broad range of innovative medicines, vaccines, and diagnostics for pets and livestock.
Side-by-side fundamentals
| Metric | MRK | ZTS | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $142.38 | $73.08 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-08) | $351.3B | $30.2B | |
| P/E as of 2026-10-08 | 113.71 | 12.02 | ZTS lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | n/a | 1.17 | |
| Net margin FY2025, SEC XBRL | +28.1% | +28.2% | ZTS higher |
| ROE FY2025, SEC XBRL | +34.7% | +80.2% | ZTS higher |
| ROA FY2025, SEC XBRL | +13.3% | +17.3% | ZTS higher |
| Debt / equity as of 2026-09-03 | 1.07 | 2.87 | MRK lower |
| Revenue growth (YoY) as of 2026-09-03 | +4.6% | +1.4% | MRK higher |
| Revenue CAGR (3y) SEC XBRL | +3.1% | +5.4% | ZTS higher |
| Dividend yield as of 2026-09-03 | +2.3% | +3.0% | ZTS higher |
| Dividend streak (yrs) SEC XBRL | 19 | 13 | MRK higher |
| Beta as of 2026-09-03 | 0.30 | 0.56 | |
| 1-year return as of 2026-10-08 close | +64.8% | -49.1% | MRK higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.